

Mankind Pharma to acquire Combihale and Daffy brands from Dr Reddy's Laboratories

Synopsis

Mankind Pharma said the market for Combihale is valued at Rs 900 crore growing at 14 per cent. The acquisition of the product is expected to strengthen the company's presence in the inhalation respiratory market segment, Mankind Pharma said in a statement. The total market for Daffy is valued at Rs 1,000 crore growing at 18 per cent, it added.



As per the terms of the definitive agreement executed between the companies, Mankind Pharma will take over the manufacturing, marketing and distribution of both the products in India. (Representative image)

Mankind Pharma on Wednesday said it has inked a pact with **Dr Reddy's Laboratories** to acquire two brands -- **Combihale** and Daffy. While Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease, **Daffy** is a soap-free **moisturising bar** for infants.

Mankind Pharma said the market for Combihale is valued at Rs 900 crore growing at 14 per cent.

The acquisition of the product is expected to strengthen the company's presence in the inhalation respiratory market segment, Mankind Pharma said in a statement.

Ad Times Prime

Unlock 1 Year Zee5 subscription only with Times Prime

VISIT SITE



Sponsored by **COLOMBIA**

The total market for Daffy is valued at Rs 1,000 crore growing at 18 per cent, it added.

ET PRIME - POPULAR INDUSTRY STORIES



Check out which Nifty50 stocks analysts recommend buying in Budget week



Tata Motors stock is soaring despite losses. Needed: positive surprise ahead to maintain momentum.



Subscribe to **ETPrime**

"We believe these brands have adequate potential to grow in the Indian market and the best part of the acquisition is that both these brands perfectly fit in our portfolio, and provides us an opportunity to grow and build the respiratory and dermatology business further," Mankind Pharma President Atish Majumdar noted.

As per the terms of the definitive agreement executed between the companies, Mankind Pharma will take over the manufacturing, marketing and distribution of both the products in India.

The entire integration and transition of the brands is expected to be completed by March 2022.

(Catch all the **Business News**, **Breaking News** Events and **Latest News** Updates on **The Economic Times**.)

...more

ETPrime stories of the day



UNDER THE LENS

From Ashneer vs. BharatPe's board to an ITC lawsuit: How is Shwetank Jain in two hot soups at once?

8 mins read



GREEN TECH

Keep it cool with phase-change materials: how home-grown Pluss is doing the job without refrigeration

7 mins read



RECENT HIT

Happy hours: as price war hots up between domestic, foreign alco-bev brands, consumers say cheers!

11 mins read



Subscribe to **ETPrime**

Feedback

BACK TO TOP